All In Biotech

Drug Trial Radar · NCT06179069

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

339

Planned (sponsor's estimate)

Start

Jan 23, 2024

Primary completion

May 30, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Zai Lab (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Zai Lab (US) LLC
First posted
Dec 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer

Conditions

  • SCLC

Interventions

  • ZL-1310Drug

    Drug: ZL-1310

  • AtezolizumabDrug

    Drug Atezolizumab

  • CarboplatinDrug

    Drug Carboplatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities of ZL-1310 as a single agent (Part 1A), in combination with Atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)Time frame: up to 24 months
  2. Incidence of Treatment Emergent Adverse-Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)Time frame: up to 24 months
  3. Incidence of Serious Adverse Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)Time frame: up to 24 months
  4. Incidence of Treatment Emergent Adverse Events of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3) and in combination with atezolizumab and carboplatin (Part 4)Time frame: up to 24 months
  5. Incidence of Serious Adverse-Events (SAEs) of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)Time frame: up to 24 months
  6. Antitumor activity per RECIST v1.1 by investigator's assessment of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)Time frame: up to 24 months
  7. Objective response rate (ORR) per RECIST v1.1 of ZL-1310 as a single agent (Part 2) and in combination with atezolizumab and carboplatin (Part 4)Time frame: up to 24 months
  8. Disease control rate (DCR) per RECIST v1.1 of ZL-1310 in combination with atezolizumabTime frame: up to 24 months

Locations

41 sites in 4 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Withdrawn

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Sarah Cannon Research Institute

    Sarasota, Florida · Recruiting

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • University of Pittsburgh Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Withdrawn

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Withdrawn

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Withdrawn

  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China · Terminated

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Terminated

  • Jilin Cancer Hospital

    Ch’ang-ch’un, Jilin, China · Active not recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China · Withdrawn

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Withdrawn

  • Affiliated Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Recruiting

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichaun, China · Recruiting

  • Rabin Medical Center

    Petah Tikva, Central District, Israel · Recruiting

  • The Chaim Sheba Medical Center

    Ramat Gan, Central District, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center Ichilov

    Tel Aviv, Tel Aviv, Israel · Recruiting

  • START Barcelona_HM Nou Delfos

    Barcelona, Spain · Recruiting

  • START MADRID_Hospital Universitario HM Sanchinarro

    Madrid, Spain · Recruiting

  • Hospital Regional Universitario de Malaga - Hospital General H

    Málaga, Spain · Recruiting

  • NEXT Oncology - Hospital Quironsalud Madrid

    Pozuelo de Alarcón, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Spain · Recruiting

  • Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON

    Barcelona, Barcelona, Spain · Recruiting

  • Hospital Universitario Ramon y Cajal

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario Virgen Macarena

    Seville, Sevilla, Spain · Recruiting

  • Hospital Clinico Universitario de Valencia

    Valencia, Valencia, Spain · Recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.